Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway
Marianne C Astor, Kristian Løvås, Aleksandra Debowska, Erik F Eriksen, Johan A Evang, Christian Fossum, Kristian J Fougner, Synnøve E Holte, Kari Lima, Ragnar B Moe, Anne Grethe Myhre, E Helen Kemp, Bjørn G Nedrebø, Johan Svartberg, Eystein S Husebye, Marianne C Astor, Kristian Løvås, Aleksandra Debowska, Erik F Eriksen, Johan A Evang, Christian Fossum, Kristian J Fougner, Synnøve E Holte, Kari Lima, Ragnar B Moe, Anne Grethe Myhre, E Helen Kemp, Bjørn G Nedrebø, Johan Svartberg, Eystein S Husebye
Abstract
Objective: The epidemiology of hypoparathyroidism (HP) is largely unknown. We aimed to determine prevalence, etiologies, health related quality of life (HRQOL) and treatment pattern of HP.
Methods: Patients with HP and 22q11 deletion syndrome (DiGeorge syndrome) were identified in electronic hospital registries. All identified patients were invited to participate in a survey. Among patients who responded, HRQOL was determined by Short Form 36 and Hospital Anxiety and Depression scale. Autoantibodies were measured and candidate genes (CaSR, AIRE, GATA3, and 22q11-deletion) were sequenced for classification of etiology.
Results: We identified 522 patients (511 alive) and estimated overall prevalence at 102 per million divided among postsurgical HP (64 per million), nonsurgical HP (30 per million), and pseudo-HP (8 per million). Nonsurgical HP comprised autosomal dominant hypocalcemia (21%), autoimmune polyendocrine syndrome type 1 (17%), DiGeorge/22q11 deletion syndrome (15%), idiopathic HP (44%), and others (4%). Among the 283 respondents (median age, 53 years [range, 9-89], 75% females), seven formerly classified as idiopathic were reclassified after genetic and immunological analyses, whereas 26 (37% of nonsurgical HP) remained idiopathic. Most were treated with vitamin D (94%) and calcium (70%), and 10 received PTH. HP patients scored significantly worse than the normative population on Short Form 36 and Hospital Anxiety and Depression scale; patients with postsurgical scored worse than those with nonsurgical HP and pseudo-HP, especially on physical health.
Conclusions: We found higher prevalence of nonsurgical HP in Norway than reported elsewhere. Genetic testing and autoimmunity screening of idiopathic HP identified a specific cause in 21%. Further research is necessary to unravel the causes of idiopathic HP and to improve the reduced HRQOL reported by HP patients.
References
- Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277–2285.
- Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30:1738–1744.
- Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf). 2016;84:904–911.
- Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28:2570–2576.
- Nakamura Y, Matsumoto T, Tamakoshi A, et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol. 2000;10:29–33.
- Zlotgora J, Cohen T. Idiopathic hypoparathyroidism in Israel. Israel J Med Sci. 1981;17:53–54.
- Raue F, Pichl J, Dorr HG, et al. Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. Clin Endocrinol (Oxf). 2011;75:760–765.
- Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013;368:2476–2486.
- Orlova EM, Bukina AM, Kuznetsova ES, et al. Autoimmune polyglandular syndrome type 1 in Russian patients: clinical variants and autoimmune regulator mutations. Hormone Res Paediatr. 2010;73:449–457.
- Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab. 2007;92:595–603.
- Alimohammadi M, Bjorklund P, Hallgren A, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med. 2008;358:1018–1028.
- Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289.
- Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab. 2004;89:548–556.
- Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet. 2007;370:1443–1452.
- Lima K, Abrahamsen TG, Wolff AB, et al. Hypoparathyroidism and autoimmunity in the 22q11.2 deletion syndrome. Eur J Endocrinol. 2011;165:345–352.
- Lima K, Folling I, Eiklid KL, Natvig S, Abrahamsen TG. Age-dependent clinical problems in a Norwegian national survey of patients with the 22q11.2 deletion syndrome. Eur J Pediatr. 2010;169:983–989.
- Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173:G1–G20.
- Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507–4514.
- Bilezikian JP, Khan A, Potts JT, Jr., et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317–2337.
- Oftedal BE, Wolff AS, Bratland E, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. ClinI Immunol. 2008;129:163–169.
- Kemp EH, Habibullah M, Kluger N, et al. Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in Finnish APECED patients. J Clin Endocrinol Metab. 2014;99:1064–1071.
- Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998;26:250–258.
- NTNU HUNT Research Centre HUNT databank. Accessed May 17, 2016.
- Statistics Norway 2015 Population statistics. Accessed May 17, 2016.
- Sorheim JI, Husebye ES, Nedrebo BG, et al. Phenotypic variation in a large family with autosomal dominant hypocalcaemia. Hormone Res Paediatr. 2010;74:399–405.
- Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128–136.
- Tomar N, Kaushal E, Das M, Gupta N, Betterle C, Goswami R. Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:1219–1226.
- Cervato S, Morlin L, Albergoni MP, et al. AIRE gene mutations and autoantibodies to interferon omega in patients with chronic hypoparathyroidism without APECED. Clin Endocrinol (Oxf). 2010;73:630–636.
- Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH (1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98:2356–2361.
- Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25:1717–1726.
- Santonati A, Palermo A, Maddaloni E, et al. PTH(1–34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life. J Clin Endocrinol Metab. 2015;100:3590–3597.
- Lovas K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf). 2002;56:581–588.
- Nermoen I, Husebye ES, Svartberg J, Lovas K. Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. Eur J Endocrinol. 2010;163:453–459.
- Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99:3694–3699.
- Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet. 2013;1:275–283.
- US FDA 2014 Briefing document for the Endocrinologic and Metabolic Drugs Advisory Committee. Natpara (rhPTH[1–84]) for injection: a replacement for endogenous parathyroid hormone (1–84) for the long term treatment of hypoparathyroidsm. Accessed May 17, 2016.
- Engum A, Bjoro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function–a clinical fact or an artefact? Acta Psychiatr Scand. 2002;106:27–34.
- Felde G, Bjelland I, Hunskaar S. Anxiety and depression associated with incontinence in middle-aged women: a large Norwegian cross-sectional study. Int Urogynecol J. 2012;23:299–306.
- Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215–222.
- Hannan FM, Nesbit MA, Zhang C, et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012;21:2768–2778.
- Mannstadt M, Bertrand G, Muresan M, et al. Dominant-negative GCMB mutations cause an autosomal dominant form of hypoparathyroidism. J Clin Endocrinol Metab. 2008;93:3568–3576.
- Oskarsdottir S, Persson C, Eriksson BO, Fasth A. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr. 2005;164:146–153.
- Upadhyay J, Steenkamp DW, Milunsky JM. The syndrome of hypoparathyroidism, deafness, and renal anomalies. Endocr Pract. 2013;19:1035–1042.
- Parvari R, Hershkovitz E, Grossman N, et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet. 2002;32:448–452.
- Unger S, Gorna MW, Le Bechec A, et al. FAM111A mutations result in hypoparathyroidism and impaired skeletal development. Am J Hum Genet. 2013;92:990–995.
- Albaramki J, Akl K, Al-Muhtaseb A, et al. Sanjad Sakati syndrome: a case series from Jordan. East Mediterr Health J. 2012;18:527–531.
- Misceo D, Holmgren A, Louch WE, et al. A dominant STIM1 mutation causes Stormorken syndrome. Hum Mut. 2014;35:556–564.
- Lemos MC, Thakker RV. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. Hum Mut. 2015;36:11–19.
Source: PubMed